Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium

Neurocrine Biosciences (NBIX) is moving to acquire Soleno Therapeutics (SLNO) for $2.9 billion in a deal that could expand its presence in rare genetic disorder